Interferon alpha 5 and human serum albumin fused protein: strategies for cloning and display of genetic instability

Abstract

A prolonged action interferon alpha-5 has a potential to become an effective pharmaceutical preparation for hepatitis C treatment. The family of interferon alpha proteins has the greatest antiviral activities against hepC infections in all the interferon families, and IFNa5 protein is the only subtype expressed in healthy liver. The in vivo circulation time of interferon alpha 5 can be prolonged by fusing this protein with human serum albumin on genetic level. Different cloning strategies were performed for insertion of fused protein into various expression strains and several problems of genetic instability were encountered.